| URL | https://www.genengnews.com/topics/bioprocessing/vg |
| Source | Genetic Engineering and Biotechnology News |
| Date Published | 10/14/2022 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | VGXI |
| Parent company | GeneOne |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | Conroe |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Proximity to customers/market |